GlycoMimetics, Inc. Profile Avatar - Palmy Investing

GlycoMimetics, Inc.

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inh…

Biotechnology
US, Rockville [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

GlycoMimetics, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

GlycoMimetics, Inc. can't present revenue by segment

Get PRO Today

With PRO you can bypass the blur for the segment revenues of GlycoMimetics, Inc..

If you want to see a demo, head over to the financial segments of AAPL

End of GLYC's Analysis
CIK: 1253689 CUSIP: 38000Q102 ISIN: US38000Q1022 LEI: - UEI: -
Secondary Listings
GLYC has no secondary listings inside our databases.